These purchases signal continued confidence in 89bio's prospects, as the company continues its work in pharmaceutical ...

(ETNB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C.

Inc.'s results from ENTRUST study on pegozafermin for Severe Hypertriglyceridemia expected in 2025. Click for this updated ...

Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Weiss Ratings reiterated their sell (d-) rating on shares of 89bio (NASDAQ:ETNB – Free Report) in a research note released on Saturday,Weiss Ratings reports. A number of other research analysts also ...

Inc. (NASDAQ:ETNB – Get Free Report)’s share price hit a new 52-week low during trading on Friday following insider selling activity. The stock traded as low as $5.99 and last traded at $6.09, with a ...

(ETNB) provided a corporate update and business outlook for 2025. Completed enrollment in Phase 3 ENTRUST trial in patients with severe ...

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The ...

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options.

CEO of 89bio. “We remain confident in pegozafermin’s potential as a potent anti-fibrotic agent with broad cardio-metabolic benefits. With a strengthened leadership team, commercial-scale ...